CD79A and metabolic dysfunction-associated steatohepatitis: In patients with non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), higher IgG levels were associated with increased risks of hepatic decompensation and mortality [18], and serum IgA levels were independent predictors of advanced fibrosis [19,20].